非商业资助者的试验注册、摘要结果获取和个体患者数据可及性政策。
Noncommercial Funders' Policies on Trial Registration, Access to Summary Results, and Individual Patient Data Availability.
机构信息
EBM Datalab, University of Oxford, Oxford, United Kingdom.
出版信息
JAMA. 2018 Apr 24;319(16):1721-1723. doi: 10.1001/jama.2018.2841.
Abstract
This study summarizes policies of the top 20 noncommercial funders of health research regarding trial registration, access to summary results, and individual patient data availability.
摘要
本研究总结了排名前 20 的非商业性卫生研究资助者在临床试验注册、获取摘要结果和个体患者数据可用性方面的政策。
相似文献
1
Noncommercial Funders' Policies on Trial Registration, Access to Summary Results, and Individual Patient Data Availability.非商业资助者的试验注册、摘要结果获取和个体患者数据可及性政策。
JAMA. 2018 Apr 24;319(16):1721-1723. doi: 10.1001/jama.2018.2841.
2
Noncommercial US Funders' Policies on Trial Registration, Access to Summary Results, and Individual Patient Data Availability.非商业性美国资助者的试验注册、摘要结果获取和个体患者数据可及性政策。
JAMA Netw Open. 2019 Jan 4;2(1):e187498. doi: 10.1001/jamanetworkopen.2018.7498.
3
Expanding disclosure of conflicts of interest: the views of stakeholders.扩大利益冲突的披露范围：利益相关者的观点。
IRB. 2003 Jan-Feb;25(1):1-8.
4
Gag clauses in clinical-trial agreements.临床试验协议中的保密条款。
N Engl J Med. 2005 May 26;352(21):2160-2. doi: 10.1056/NEJMp048353.
5
Public access to NIH-funded research.公众对国立卫生研究院资助研究的获取。
N Engl J Med. 2005 Apr 28;352(17):1739-41. doi: 10.1056/NEJMp058088.
6
Mandatory registration of clinical trials.临床试验的强制注册。
Ceylon Med J. 2005 Dec;50(4):139-41. doi: 10.4038/cmj.v50i4.1401.
7
Adoption of World Health Organization Best Practices in Clinical Trial Transparency Among European Medical Research Funder Policies.世界卫生组织临床试验透明度最佳实践在欧洲医学研究资助者政策中的采用。
JAMA Netw Open. 2022 Aug 1;5(8):e2222378. doi: 10.1001/jamanetworkopen.2022.22378.
8
Global health equity in United Kingdom university research: a landscape of current policies and practices.英国大学研究中的全球卫生公平性：当前政策与实践概况
Health Res Policy Syst. 2016 Oct 10;14(1):76. doi: 10.1186/s12961-016-0148-6.
9
Industry-sponsored clinical research: a broken system.行业资助的临床研究：一个漏洞百出的体系。
JAMA. 2008 Sep 3;300(9):1069-71. doi: 10.1001/jama.300.9.1069.
10
Which studies should be registered on a clinical trials registry?哪些研究应该在临床试验注册机构进行注册？
J Adv Nurs. 2018 Nov;74(11):2479. doi: 10.1111/jan.13696. Epub 2018 Jul 11.
引用本文的文献
1
Journal data-sharing policies and its impact in publications: A cross-sectional study protocol.期刊数据共享政策及其对出版物的影响：一项横断面研究方案。
PLoS One. 2025 Sep 2;20(9):e0331697. doi: 10.1371/journal.pone.0331697. eCollection 2025.
2
Perceptions and Opinions Towards Data-Sharing: A Survey of Addiction Journal Editorial Board Members.对数据共享的认知与看法：成瘾学期刊编辑委员会成员调查
J Sci Pract Integr. 2022;2022. doi: 10.35122/001c.35597. Epub 2022 May 19.
3
Prevalence and predictors of data and code sharing in the medical and health sciences: systematic review with meta-analysis of individual participant data.在医学和健康科学领域中，数据和代码共享的流行率及其预测因素：基于个体参与者数据的系统评价和荟萃分析。
BMJ. 2023 Jul 11;382:e075767. doi: 10.1136/bmj-2023-075767.
4
Discrepancies between FDA documents and ClinicalTrials.gov for Orphan Drug-related clinical trial data.美国食品药品监督管理局（FDA）文件与临床试验.gov网站上关于孤儿药相关临床试验数据的差异。
PLOS Glob Public Health. 2022 Apr 22;2(4):e0000261. doi: 10.1371/journal.pgph.0000261. eCollection 2022.
5
Adoption of World Health Organization Best Practices in Clinical Trial Transparency Among European Medical Research Funder Policies.世界卫生组织临床试验透明度最佳实践在欧洲医学研究资助者政策中的采用。
JAMA Netw Open. 2022 Aug 1;5(8):e2222378. doi: 10.1001/jamanetworkopen.2022.22378.
6
Status, use and impact of sharing individual participant data from clinical trials: a scoping review.临床试验个体参与者数据共享的现状、使用和影响：范围综述。
BMJ Open. 2021 Aug 18;11(8):e049228. doi: 10.1136/bmjopen-2021-049228.
7
Characteristics and trends of clinical studies primarily sponsored by China in WHO primary registries between 2009 and 2018: a cross-sectional survey.2009 年至 2018 年中国在世界卫生组织主要登记处资助的临床研究的特征和趋势：一项横断面调查。
BMJ Open. 2020 Nov 20;10(11):e037262. doi: 10.1136/bmjopen-2020-037262.
8
Funders' data-sharing policies in therapeutic research: A survey of commercial and non-commercial funders.治疗性研究中资助者的数据共享政策：对商业和非商业资助者的调查。
PLoS One. 2020 Aug 20;15(8):e0237464. doi: 10.1371/journal.pone.0237464. eCollection 2020.
9
Challenges for funders in monitoring compliance with policies on clinical trials registration and reporting: analysis of funding and registry data in the UK.资助者在监测临床试验注册和报告政策合规性方面面临的挑战：对英国资助和注册数据的分析
BMJ Open. 2020 Feb 17;10(2):e035283. doi: 10.1136/bmjopen-2019-035283.
本文引用的文献
1
Pharmaceutical companies' policies on access to trial data, results, and methods: audit study.制药公司获取试验数据、结果和方法的政策：审计研究。
BMJ. 2017 Jul 26;358:j3334. doi: 10.1136/bmj.j3334.
2
What are funders doing to minimise waste in research?资助者们在采取哪些措施来尽量减少研究中的浪费现象？
Lancet. 2017 Mar 11;389(10073):1006-1007. doi: 10.1016/S0140-6736(17)30657-8.
3
The 10 largest public and philanthropic funders of health research in the world: what they fund and how they distribute their funds.全球十大健康研究公共及慈善资助者：他们资助的领域以及资金分配方式。
Health Res Policy Syst. 2016 Feb 18;14:12. doi: 10.1186/s12961-015-0074-z.
4
Increasing value and reducing waste in biomedical research: who's listening?增加生物医学研究的价值和减少浪费：谁在倾听？
Lancet. 2016 Apr 9;387(10027):1573-1586. doi: 10.1016/S0140-6736(15)00307-4. Epub 2015 Sep 27.
5
Evidence-informed recommendations to reduce dissemination bias in clinical research: conclusions from the OPEN (Overcome failure to Publish nEgative fiNdings) project based on an international consensus meeting.基于国际共识会议的“开放（克服阴性结果发表失败）”项目得出的减少临床研究中传播偏倚的循证建议。
BMJ Open. 2015 May 5;5(5):e006666. doi: 10.1136/bmjopen-2014-006666.
Zotero 插件